statements regarding our plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary and the expectation that such customer set will be limited
As more consumers eat less per occasion, avoid indulgent items, and prioritize protein, QSR operators need to move beyond a model built primarily on calorie density, upsizing, and impulse add-ons
We also check for any health issues that might make GLP-1 meds unsafe for you, such as a history of pancreatitis, thyroid cancer, or some digestive problems
For example, a pharmacy may make a liquid version of a drug that only comes in pill form for a patient who has trouble swallowing
For most people there are few side effects
If peptides are on your roadmap, do you have specialized counsel and a plan that can adapt to a single regulatory decision